PT2179737E - Método para modular a capacidade de resposta aos esteróides - Google Patents

Método para modular a capacidade de resposta aos esteróides

Info

Publication number
PT2179737E
PT2179737E PT91675389T PT09167538T PT2179737E PT 2179737 E PT2179737 E PT 2179737E PT 91675389 T PT91675389 T PT 91675389T PT 09167538 T PT09167538 T PT 09167538T PT 2179737 E PT2179737 E PT 2179737E
Authority
PT
Portugal
Prior art keywords
steroids
oligonucleotide
responding
modulating responsiveness
steroid
Prior art date
Application number
PT91675389T
Other languages
English (en)
Inventor
Ann-Kristin Spiik
Robert Loefberg
Oliver Von Stein
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of PT2179737E publication Critical patent/PT2179737E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT91675389T 2005-07-01 2006-06-30 Método para modular a capacidade de resposta aos esteróides PT2179737E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69605005P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
PT2179737E true PT2179737E (pt) 2013-12-05

Family

ID=37604740

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91675389T PT2179737E (pt) 2005-07-01 2006-06-30 Método para modular a capacidade de resposta aos esteróides

Country Status (11)

Country Link
US (2) US8148341B2 (pt)
EP (2) EP2179737B1 (pt)
JP (2) JP5208734B2 (pt)
AT (1) ATE439135T1 (pt)
DE (1) DE602006008473D1 (pt)
DK (1) DK2179737T3 (pt)
ES (2) ES2435531T3 (pt)
PL (1) PL2179737T3 (pt)
PT (1) PT2179737E (pt)
SI (1) SI2179737T1 (pt)
WO (1) WO2007004979A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006266503B2 (en) * 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
EP2179737B1 (en) * 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids
US8895522B2 (en) 2005-10-28 2014-11-25 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
US8410068B2 (en) 2007-10-05 2013-04-02 Index Pharmaceuticals Ab Compounds for the treatment or alleviation of edema, and methods for their use
CN101896186A (zh) * 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US20110182880A1 (en) * 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
AU2009311753B2 (en) * 2008-11-04 2015-01-15 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (pt) 1992-07-23 1995-04-01 Tri Clover Inc
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
DE69739515D1 (de) 1996-01-30 2009-09-10 Univ California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
SE9602300D0 (sv) 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002513763A (ja) 1998-05-06 2002-05-14 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Ｃｐｇオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法
WO1999058118A2 (en) 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP4663047B2 (ja) * 1998-07-13 2011-03-30 株式会社半導体エネルギー研究所 レーザー照射装置及び半導体装置の作製方法
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
AP1775A (en) 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1688147A1 (en) 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US6294382B1 (en) 2000-11-27 2001-09-25 Isis Pharmaceuticals, Inc. Antisense modulation of SRC-1 expression
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) 2001-03-01 2002-09-11 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
JP4397571B2 (ja) * 2001-09-25 2010-01-13 株式会社半導体エネルギー研究所 レーザ照射方法およびレーザ照射装置、並びに半導体装置の作製方法
IL160837A0 (en) 2001-10-05 2004-08-31 Coley Pharm Gmbh Toll-like receptor 3 signaling agonists and antagonists
KR20050048539A (ko) 2001-10-06 2005-05-24 메리얼엘엘씨 ＣｐＧ 제제 및 관련된 방법
US7105048B2 (en) * 2001-11-30 2006-09-12 Semiconductor Energy Laboratory Co., Ltd. Laser irradiation apparatus
JP3949564B2 (ja) * 2001-11-30 2007-07-25 株式会社半導体エネルギー研究所 レーザ照射装置及び半導体装置の作製方法
JP2005526497A (ja) 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
US6977775B2 (en) * 2002-05-17 2005-12-20 Sharp Kabushiki Kaisha Method and apparatus for crystallizing semiconductor with laser beams
JP4474108B2 (ja) * 2002-09-02 2010-06-02 株式会社 日立ディスプレイズ 表示装置とその製造方法および製造装置
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
EP1625140A4 (en) 2002-12-23 2008-06-18 Dynavax Tech Corp BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
DK1575977T3 (da) 2002-12-23 2009-11-09 Dynavax Tech Corp Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
WO2004064782A2 (en) 2003-01-16 2004-08-05 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
WO2004087203A2 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
MXPA05012421A (es) 2003-05-16 2006-02-22 Hybridon Inc Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
WO2005080567A1 (de) 2004-02-20 2005-09-01 Mologen Ag Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
JP2007523173A (ja) 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
HUE036894T2 (hu) 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
JP5072197B2 (ja) * 2004-06-18 2012-11-14 株式会社半導体エネルギー研究所 レーザ照射装置およびレーザ照射方法
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
CA2578775C (en) 2004-09-01 2016-05-03 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
KR20080008350A (ko) * 2005-04-08 2008-01-23 콜레이 파마시티컬 그룹, 인코포레이티드 감염성 질환에 의해 악화된 천식의 치료 방법
AU2006266503B2 (en) * 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
EP2179737B1 (en) * 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids

Also Published As

Publication number Publication date
US20080318885A1 (en) 2008-12-25
ES2435531T3 (es) 2013-12-20
PL2179737T3 (pl) 2014-01-31
ES2330884T3 (es) 2009-12-16
WO2007004979A1 (en) 2007-01-11
JP2008544984A (ja) 2008-12-11
EP1904077A1 (en) 2008-04-02
EP2179737A3 (en) 2010-08-25
US8148341B2 (en) 2012-04-03
EP1904077B1 (en) 2009-08-12
ATE439135T1 (de) 2009-08-15
JP2012193192A (ja) 2012-10-11
DE602006008473D1 (de) 2009-09-24
EP2179737B1 (en) 2013-08-14
JP5208734B2 (ja) 2013-06-12
SI2179737T1 (sl) 2014-02-28
US20120172420A1 (en) 2012-07-05
EP2179737A2 (en) 2010-04-28
DK2179737T3 (da) 2013-11-11
JP5886699B2 (ja) 2016-03-16
US8569257B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
PL2179737T3 (pl) Sposób do modulowania wrażliwości na steroidy
SI2269622T1 (sl) CpG OLIGONUKLEOTIDI, KI SE UPORABLJAJO ZA IZBOLJĹ ANJE STEROIDNE AKTIVNOSTI PRI STEROIDNO ODVISNIH BOLNIKIH
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
IL201479A (en) Use of tapentadol for the preparation of pain medication
BRPI0512944A (pt) agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
UA90467C2 (ru) Применение пептидных соединений для лечения боли при болезненой диабетической невропатии
HK1110221A1 (en) Use of prodrugs for ocular intravitreous administration
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
BR112012004284B8 (pt) ácidos biliares poli-hidroxilados para tratamento de transtornos biliares
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
WO2007135505A3 (en) Veterinary pharmaceutical compositions for the treatment of pain and inflammation
IL198202A0 (en) Peptide-cytotoxic conjugates
TW200806293A (en) Methods of treatment with CETP inhibitors
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
HUP0600489A2 (en) Use of echinacea or preparations made thereof for the manufacture of pharmaceutical compositions for the treatment of anxiety
UA98500C2 (en) Substituted acylanilides and methods of use thereof
PT1948194E (pt) Utilização de ácido clodrónico para o tratamento de podotrocleose
FI20080543L (fi) Kauha
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders